Safety of Creatinine Supplements

Creatine Supplementation: What Clinicians Should Know About Efficacy, Safety, and Clinical Implications

Creatine monohydrate is among the most studied dietary supplements, with substantial evidence supporting ergogenic benefits in high-intensity resistance training and an excellent safety profile in healthy populations when used at standard doses 1. However, creatine metabolism produces creatinine as a byproduct, creating important clinical considerations for kidney function assessment. A 2025 meta-analysis of 21 studies confirmed that creatine causes a modest, statistically significant increase in serum creatinine without affecting glomerular filtration rate, indicating elevated creatinine reflects metabolic turnover rather than renal impairment 1. Clinicians should understand the pharmacology, appropriate use cases, regulatory limitations, and practical implications for patient counseling and laboratory interpretation.

Mechanism of action and physiological effects

Creatine (α-methyl-guanidine-acetic acid) is synthesized endogenously from glycine and arginine in the liver, kidneys, and pancreas. Approximately 95% of creatine stores reside in skeletal muscle, where it phosphorylates to phosphocreatine and serves as a rapid ATP regeneration system during high-intensity exercise 2. Dietary sources include meat and fish (≈3–5 g/kg uncooked weight), though typical omnivorous intake provides less than 1 g/day 3.

Supplementation protocols generally follow two approaches:

Alternative protocols omit loading and use 3–5 g/day continuously, achieving muscle saturation over 3–4 weeks with reduced gastrointestinal discomfort and fluid retention.

Efficacy evidence and appropriate use cases

The International Olympic Committee consensus statement identifies creatine as one of few supplements with good evidence of performance benefit, alongside caffeine, buffering agents, and nitrate 5. Effects are highly specific to context:

• Demonstrated benefits: Short-duration, maximum-intensity resistance training; repeated high-intensity exercise bouts; muscle glycogen replenishment when taken post-exercise; potential cognitive benefits (small effect, requires further study) 6
• No demonstrated benefit: Aerobic endurance activities; "on-field" athletic performance in most scenarios 3

Response varies considerably between individuals due to genetics, habitual diet, baseline muscle creatine stores, and training status. Vegetarians and individuals with lower baseline creatine levels demonstrate larger responses 6.

Renal safety: separating myth from evidence

Long-standing concerns about creatine nephrotoxicity stem from early case reports, animal studies, and the pharmacokinetic relationship between creatine and creatinine. These concerns persist despite accumulating safety data.

Key pharmacokinetic consideration: Creatine spontaneously converts to creatinine at approximately 2% per day 7. Increased total body creatine from supplementation elevates creatinine generation, which can falsely elevate serum creatinine without reflecting true glomerular filtration rate (GFR) decline 8.

Evidence from a 2025 systematic review and meta-analysis including 21 studies with 440 participants demonstrates:

Critically, no study demonstrated actual kidney injury with creatine supplementation in participants without pre-existing renal disease. The 2025 meta-analysis explicitly recommends that clinicians interpret elevated serum creatinine in the context of creatine supplementation with caution and consider more specific renal function markers(cystatin C, measured GFR) when accurate assessment is required 1.

Regulatory context and quality concerns

Dietary supplements, including creatine, operate under substantially different regulatory frameworks than prescription medications:

Third-party certification (USP Verified, NSF Certified for Sport) provides the best available quality assurance, as contamination with prohibited substances and variable product content remain documented concerns 5. The IOC notes that inadvertent ingestion of prohibited substances is a known risk of supplement use in elite sport 5.

Clinical scenarios requiring modified approach

Several populations warrant particular caution or avoidance:

• Pre-existing kidney disease: Limited safety data; creatine may exacerbate fluid retention and complicates GFR monitoring
• Solitary kidney/Living kidney donors: Case reports demonstrate creatine can cause misclassification of acute kidney injury due to creatinine elevation without true GFR change 9
• Pregnancy and lactation: Insufficient human data; potential osmotic effects as creatine is an osmolyte; experimental animal studies suggest fetal benefit in hypoxic conditions but clinical translation is premature 10
• Pediatric and adolescent athletes: No pediatric-specific safety data; American Academy of Pediatrics recommends against use for athletes at risk for kidney dysfunction 3
• Concurrent nephrotoxic medications: NSAIDs, aminoglycosides, and other nephrotoxic agents may increase risk in combination

Practical recommendations for patient counseling

When patients inquire about creatine supplementation, clinicians should address several key domains:

1. Realistic expectations: Benefits are modest, specific to resistance training contexts, and vary individually. Marketing claims often exceed evidence.

2. Dosing and duration: Standard maintenance dosing (3–5 g/day) appears safe long-term; loading protocols provide faster saturation but increase side effects.

3. Side effect profile: Weight gain from intramuscular water retention is consistent; gastrointestinal discomfort is dose-dependent and mitigated by divided doses or taking with meals.

4. Laboratory monitoring: Warn patients that creatine will elevate serum creatinine; inform other providers of supplementation when kidney function is assessed.

5. Quality selection: Recommend third-party certified products if patient proceeds with supplementation.

6. Discontinuation timing: For planned surgery or procedures requiring accurate kidney function assessment, recommend discontinuing 1–2 weeks prior 9.